source
- OrbiMed raises $3 billion, its biggest Asian fund yet, to boost biotech investments worldwideOrbiMed announced it has closed a $3 billion fundraising round, the largest ever for its Asia‑focused vehicle. The capital will be used to make new growth‑equity and venture investments in biotech…
- SimBioSys receives FDA clearance for Nvidia-powered AI tool to predict breast cancer recurrenceSimBioSys announced FDA clearance for its TumorSight Risk platform, an AI-driven tool that uses MRI, pathology and clinical data to assess the likelihood of breast cancer returning. The cloud-base…